Nanoform Partners With European CDMO to Advance Biologics Technology

COMPANY PROFILE
  • Nanoform Finland Plc has signed an agreement with a European CDMO partner to implement its biologics technology at the partner’s existing aseptic manufacturing facility in Germany, with a dedicated production line for biological products.
  • The companies are targeting GMP readiness in the second half of 2027 to support a planned first customer clinical trial of a subcutaneous, ultra-high-concentration suspension biologic product enabled by nanoforming.

Nanoform Finland Plc, a medicine performance-enhancing company, has signed an agreement with a European CDMO partner to implement its biologics technology at the partner’s aseptic manufacturing facility in Germany. The collaboration will establish a dedicated production line for Nanoform’s technology within the existing facility, which has capabilities for the GMP manufacture of injectable biologics, including aseptic processing and fill-and-finish.

The CDMO partner can support projects from early clinical development through commercial manufacturing. The agreement is intended to provide Nanoform’s customers with a pathway from formulation and preclinical development through GMP manufacturing and clinical trial supply, with the potential to support later commercial production.

Nanoform and its partner are targeting GMP readiness in the second half of 2027. This is intended to support a planned first customer clinical trial of a subcutaneous, ultra-high-concentration suspension biologic product enabled by nanoforming. The agreement is not expected to have an immediate material financial effect on Nanoform.

Nanoform CEO Edward Hæggström said the partnership would help accelerate customers’ progress toward clinical development with subcutaneous, ultra-high-concentration suspension products. He added that implementation work at the partner’s site is expected to take place over the coming months.

EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.